Table 1

Expression of IL-17 by mast cells, T cells and macrophages in synovial tissue

Demographics

ACPA+ RA (n = 34)

ACPA- RA (n = 25)

OA (n = 29)

P value


Age (years)

55 (32 to 80)

63 (19 to 80)

67 (42 to 83)

Gender (females/males)

22/12

14/11

21/8

Disease duration (years)

7 (0 to 28)

8 (0 to 24)

Unknown

Median IL-17+ cells

21 (0 to 118)

12 (1 to 61)

17 (0 to 50)

0.381

IL-17+ mast cells (%)

97 (40 to 100)

96 (0 to 100)

93 (0 to 100)

0.969

IL-17+ T cells (%)

0 (0 to 100)

0 (0 to 24)

2 (0 to 49)

0.558

IL-17+ MØ (%)

0 (0 to 78)

4 (0 to 100)

1 (0 to 58)

0.382

Median MCs

28 (0 to 123)

19 (0 to 92)

25 (0 to 76)

0.198

MCs (CD117+) expressing IL-17 (%)

91 (13 to 100)

83 (0 to 100)

96 (4 to 100)

0.599

T cells (CD3+), n

21 (0 to 592)

10 (0 to 115)

11 (0 to 265)

0.609

T cells (CD3+) expressing IL-17 (%)

0 (0 to 60)

0 (0 to 66)

1 (0 to 78)

0.149

MØ (CD68+), n

71 (1 to 390)

53 (1 to 302)

66 (2 to 231)

0.634

MØ (CD68+) expressing IL-17 (%)

0 (0 to 16)

0 (0 to 14)

0 (0 to 11)

0.689


ACPA: anticitrullinated protein antibody; MC: mast cell; MØ: macrophage; OA: osteoarthritis; RA: rheumatoid arthritis. Results are expressed as medians (minimum-maximum). Mast cells are defined as CD117+ cells, T cells are defined as CD3+ cells and macrophages are defined as CD68+ cells.

Suurmond et al. Arthritis Research & Therapy 2011 13:R150   doi:10.1186/ar3466

Open Data